Know Cancer

forgot password

A Phase 2, Single-Arm Study of Pralatrexate in Patients With Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Phase 2
18 Years
Not Enrolling
Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm

Thank you

Trial Information

A Phase 2, Single-Arm Study of Pralatrexate in Patients With Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder

Inclusion Criteria:

- Histologically confirmed transitional cell carcinoma of the urinary bladder. Fine
needle aspirate will not be accepted.

- Relapsed or progressed after treatment with a platinum- and/or methotrexate-based
systemic chemotherapy regimen. No more than 1 prior regimen is permitted for
recurrent/metastatic disease. Patients has had a chemotherapy-free interval of ≥ 12
months from last dose if most recent prior chemotherapy was in neoadjuvant/adjuvant
setting and has had ≥ 6-month chemotherapy-free interval in recurrent/metastatic
setting. Patient has recovered from the toxic effects of prior therapy. Previous
intravesical therapy is allowed. Prior surgical resection is allowed, as long as the
patient has recovered.

- Measurable disease outside a previously irradiated region, per Response Evaluation
Criteria in Solid Tumors (RECIST).

- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

- At least 18 years of age.

- Adequate blood, liver, and kidney function as defined by laboratory results.

- Patient has received 1.0-1.25 mg of oral folic acid daily for at least 7 days of
enrollment & 1 mg intramuscular vitamin B12 within 10 weeks of enrollment.

- Women of childbearing potential have a negative serum pregnancy test within 14 days
prior to enrollment and agree to use medically acceptable and effective birth control
from enrollment until at least 30 days after the last dose of pralatrexate.

- Men who are not surgically sterile and whose partner is of childbearing potential
must use medically safe and effective birth control start of pralatrexate until at
least 90 days after the last dose of pralatrexate.

- Accessible for repeat dosing and follow up.

- Give written informed consent.

Exclusion Criteria:

- Active concurrent primary malignancy or prior malignancies occurring within 5 years
(except non-melanoma skin cancer, in situ carcinoma of the cervix, or occult,
indolent carcinoma of the prostate). If there is a history of prior malignancies
other than those exceptions listed above, the patient must be disease free for ≥ 5
years. Patients with other prior malignancies < 5 years before study entry may still
be enrolled if they have received treatment resulting in complete resolution of the
cancer and currently have no clinical, radiologic, or laboratory evidence of active
or recurrent disease. In the case of a single extrapelvic metastatic site,
irrespective of the patient having a history of previous malignancy, a biopsy proof
of the metastatic diseased organ will be necessary.

- More than 1 previous regimen for recurrent/metastatic disease.

- Evidence of clinically significant active third-space phenomenon

- Use of investigational drugs, biologics, or devices within 28 days prior to study

- Previous exposure to other antifolates, including pralatrexate. Previous
methotrexate is allowed, only if it was part of an M-VAC or MCV regimen.

- Women who are pregnant or breastfeeding.

- Congestive Heart Failure Class III/IV according to New York Heart Association (NYHA)
Functional Classification.

- Uncontrolled hypertension.

- Human immunodeficiency virus (HIV)-positive diagnosis with a CD4 count of < 100 mm3
or detectable viral load within the past 3 months, and receiving combination
anti-retroviral therapy.

- Central nervous system metastatic disease.

- Major surgery within 2 weeks of study enrollment.

- Radiation therapy (RT) within 4 weeks (within 3 months for RT to the pelvis) prior to
study enrollment.

- Active infection or any serious underlying medical condition, which would impair the
ability of the patient to receive protocol treatment.

- Dementia or significantly altered mental status that would prohibit the understanding
and giving of informed consent or limit study compliance.

Type of Study:


Study Design:

Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective Response Rate (ORR)

Outcome Description:

The number of patients with a best overall confirmed response of either complete response (CR) or partial response (PR)

Outcome Time Frame:

Assessed at the end of each even-numbered cycle (every 8 weeks), or per standard of care but no more than every 12 weeks (+/- 1 week) if treatment has ended for up to 2 years after enrollment.

Safety Issue:


Principal Investigator

Garry Weems, Pharm.D.

Investigator Role:

Study Director

Investigator Affiliation:

Spectrum Pharmaceuticals, Inc


United States: Food and Drug Administration

Study ID:




Start Date:

July 2008

Completion Date:

September 2011

Related Keywords:

  • Carcinoma, Transitional Cell
  • Bladder Cancer
  • Bladder Neoplasm
  • Transitional Cell Carcinoma of the Urinary Bladder
  • Transitional Cell Carcinoma
  • Bladder Cancer
  • Urinary Bladder Cancer
  • Bladder
  • Carcinoma
  • Urinary
  • Metastatic
  • Relapsed
  • Urinary Bladder Neoplasms
  • Neoplasms
  • Carcinoma
  • Carcinoma, Transitional Cell



University of Rochester Cancer Center Rochester, New York  14642
Peachtree Hematology/Oncology Consultants Atlanta, Georgia  30309
University of Utah, Huntsman Cancer Institute Salt Lake City, Utah  84112
The University of Arizona Health Sciences Center Tucson, Arizona  85724